Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2B, Multi-Center, Randomized, Double-blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs. Placebo in Subjects With Moderately to Severely Active Crohn's Disease.

NCT00562887 is registered in ClinicalTrials.gov with Abbott as lead sponsor.

NCT NCT00562887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00562887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2B, Multi-Center, Randomized, Double-blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs. Placebo in Subjects With Moderately to Severely Active Crohn's Disease.
Lead sponsor
Abbott
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2007
Completion date
Not reported
Enrollment
246 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease